Sort
82,697 grants matching “vaccine development”
Anti-norovirus protease inhibitors for immunocompromised patients
$762,258Raymond F. Schinazi · Emory University · R01 · FY2024 · AI
The VesiVax® System: Vaccine Development Made Easy
$762,253Samon Ho · Molecular Express, Inc. · R44 · FY2016 · AI
Closing Research Gaps in Antiretroviral Treatment for Pregnant Women and Infants Living with HIV
$762,247Roger L Shapiro · Harvard University D/B/A Harvard School Of Public Health · P01 · FY2025 · HD
Targeting HIV reservoirs in children with HIVIS DNA and MVA-CMDR vaccines
$762,210Merlin L Robb · Henry M. Jackson Fdn For The Adv Mil/Med · U01 · FY2022 · AI
Pragmatic Implementation Science Approaches to Assess and Enhance Value of Cancer Prevention and Control in Rural Primary Care
$762,190Russell E Glasgow · University Of Colorado Denver · P50 · FY2020 · CA
Improving predictive capacity of models for universal influenza vaccine development
$762,129Richard John Webby · St. Jude Children'S Research Hospital · R01 · FY2023 · AI
A chikungunya Viral Replicon as a Platform for Antiviral Therapeutics
$762,045David E. Levy · Columbia University Health Sciences · U54 · FY2013 · AI
Mechanisms of BNT162b2 Vaccine Immunogenicity in Systemic Lupus Erythematosus or Scleroderma
$762,036Paul Joseph Utz · Stanford University · R01 · FY2024 · AI
Exploring Wolbachia for malaria control
$762,034Zhiyong Xi · Michigan State University · R01 · FY2025 · AI
Development of a Replicon RNA-based Universal Vaccine against Dengue and Zika
$761,992Sujan Shresta · La Jolla Institute For Immunology · R56 · FY2020 · AI
Hydrogel-based lymphoid tissues for generation of activated human B cells and delivery in vivo
$761,981Ankur Singh · Georgia Institute Of Technology · R01 · FY2025 · AI
Integrative Omics of HepB Vaccine Response in Co-Infection with Parasites
$761,944Elias K Haddad · Drexel University · U19 · FY2020 · AI
Functional profiling of OSP-specific and other antibodies during shigella infection
$761,935Edward T. Ryan · Massachusetts General Hospital · R01 · FY2022 · AI
Functional profiling of OSP-specific and other antibodies during shigella infection
$761,935Edward T. Ryan · Massachusetts General Hospital · R01 · FY2023 · AI
Functional profiling of OSP-specific and other antibodies during shigella infection
$761,935Edward T. Ryan · Massachusetts General Hospital · R01 · FY2021 · AI
Functional profiling of OSP-specific and other antibodies during shigella infection
$761,935Edward T. Ryan · Massachusetts General Hospital · R01 · FY2024 · AI
Development of a Vaccine for HIVAIDS: Cellular Immunity
$761,876Marjorie Robert-Guroff · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi
$761,873Linden T Hu · Tufts University Boston · R01 · FY2022 · AI
St. Jude-Memphis Adolescent Trials Unit
$761,872Patricia Michele Flynn · St. Jude Children'S Research Hospital · U01 · FY2008 · HD
Physical Resources Core
$761,840Michael Anthony Moody · Duke University · P01 · FY2018 · AI
Modeling Mechanisms of Adjuvanted Influenza Vaccine Induced IgG Repertoire Diversity and Heterosubtypic Immunity
$761,818Martin S Zand · University Of Rochester · R01 · FY2017 · AI
Role of gamma/delta T cells in Vaccine Induced Immunity
$761,813Daniel F. Hoft · Saint Louis University · R01 · FY2018 · AI
New approach for immune modulation against T1D
$761,809Weston Daniel · Evoq Therapeutics, Inc. · R44 · FY2023 · DK
Immunotherapeutics Against Other Filovirus Threats
$761,804Jonathan R. Lai · Scripps Research Institute, The · U19 · FY2017 · AI
Structural and functional basis of ultra potent CHKV neutralization by human mAbs
$761,802James E Crowe · Vanderbilt University · R01 · FY2015 · AI